Trial Outcomes & Findings for Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression (NCT NCT00926393)

NCT ID: NCT00926393

Last Updated: 2011-05-11

Results Overview

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

139 participants

Primary outcome timeframe

At 1 hour post-dose, Day 2 (50 mg)

Results posted on

2011-05-11

Participant Flow

A 7-day, inpatient, multicenter, double-blind, double-dummy, randomized, parallel group, Phase IV study was done to compare the tolerability of quetiapine IR with quetiapine XR during initial dose escalation in patients with bipolar depression. In total 139 patients were randomized in 15 centers in the USA between June and August 2009.

Patients must have DSM-IV-TR documented bipolar I or bipolar II, most recent episode depressed, and outpatient status at enrollment . Patients must not have another current, major disorder that is symptomatic or has required treatment within 6 months of enrollment.

Participant milestones

Participant milestones
Measure
Quetiapine IR
Quetiapine fumarate Immediate Release
Quetiapine XR
Quetiapine fumarate Extended Release
Overall Study
STARTED
69
70
Overall Study
COMPLETED
67
67
Overall Study
NOT COMPLETED
2
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Quetiapine IR
Quetiapine fumarate Immediate Release
Quetiapine XR
Quetiapine fumarate Extended Release
Overall Study
Withdrawal by Subject
1
2
Overall Study
Adverse Event
1
1

Baseline Characteristics

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Total
n=139 Participants
Total of all reporting groups
Age, Customized
18-39
28 Participants
n=99 Participants
31 Participants
n=107 Participants
59 Participants
n=206 Participants
Age, Customized
40-50
41 Participants
n=99 Participants
39 Participants
n=107 Participants
80 Participants
n=206 Participants
Sex: Female, Male
Female
32 Participants
n=99 Participants
34 Participants
n=107 Participants
66 Participants
n=206 Participants
Sex: Female, Male
Male
37 Participants
n=99 Participants
36 Participants
n=107 Participants
73 Participants
n=206 Participants

PRIMARY outcome

Timeframe: At 1 hour post-dose, Day 2 (50 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2)
45.022 units on scale
Interval 38.287 to 51.758
32.472 units on scale
Interval 25.935 to 39.009

SECONDARY outcome

Timeframe: At 1 hour post-dose, Day 3 (100 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Modified Bond-Lader Visual Analog Scale Score After 100-mg Dose (Day 3)
51.521 units on scale
Standard Error 3.341 • Interval 3.341 to
29.146 units on scale
Standard Error 3.239 • Interval 3.239 to

SECONDARY outcome

Timeframe: At 1 hour post-dose, Day 4 (200 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Modified Bond-Lader Visual Analog Scale Score After 200-mg Dose (Day 4)
48.336 units on scale
Standard Error 3.703 • Interval 3.703 to
30.130 units on scale
Standard Error 3.609 • Interval 3.609 to

SECONDARY outcome

Timeframe: At 1 hour post-dose, Day 5 (300 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 5)
49.414 units on scale
Standard Error 4.347 • Interval 4.347 to
32.626 units on scale
Standard Error 4.258 • Interval 4.258 to

SECONDARY outcome

Timeframe: At 1 hour post-dose, Day 6 (300 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 6)
48.959 units on scale
Standard Error 4.015 • Interval 4.015 to
30.144 units on scale
Standard Error 3.910 • Interval 3.91 to

SECONDARY outcome

Timeframe: During Day 2 (50 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

The Maximum Intensity Modified Bond-Lader VAS after dose (MaxIntVAS) is calculated as maximum possible value of VAS during that day at any from 1, 2, 3, 4, 5, 12, 13, 14 hours post-dose assessments

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
99.929 units on scale
Standard Error 1.353 • Interval 1.353 to
96.937 units on scale
Standard Error 1.313 • Interval 1.313 to

SECONDARY outcome

Timeframe: During Day 2 (50 mg)

Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.

Time (Tmax) to Maximum Intensity Modified Bond-Lader VAS after dose is corresponding assessment time (one from 1, 2, 3, 4, 5, 12, 13, 14 hours post-dose) of MaxIntVas

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Time to Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
3.685 Hours
Standard Error 0.246 • Interval 0.246 to
4.254 Hours
Standard Error 0.239 • Interval 0.239 to

SECONDARY outcome

Timeframe: During Day 2 (50 mg)

Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.

Area under the Modified Bond-Lader VAS-time curve is calculated by the linear trapezoidal formula which equals sum of (Ck+Ck+1)/2 multiplied by the time interval between k and k+1 observations, where Ck and Ck+1 are the corresponding the intensity of sedation evaluations measured by the Modified Bond-Lader VAS from 1 to 14 hours post-dose

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
Area Under the Modified Bond-Lader Visual Analog Scale-time Curve
1061.12 mm * hour
Standard Error 31.559 • Interval 31.559 to
988.842 mm * hour
Standard Error 30.612 • Interval 30.612 to

SECONDARY outcome

Timeframe: Randomization to Day 7

Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.

SAS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4, higher scores indicate greater severity of Parkinsonian symptoms. Change : total score at day 7 minus total score at randomization. Increase in Change of total score indicates an increase in extrapyramidal motor symptoms.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Change in Simpson-Angus Scale (SAS) Total Score
-0.1 units on scale
Standard Deviation 0.8
0.1 units on scale
Standard Deviation 0.5

SECONDARY outcome

Timeframe: Randomization to Day 7

Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.

BARS global score is the 4th individual-item score on the BARS scale,the Global Assessment of Akathisia, with the score ranging from 0 to 5. Change : score at day 7 minus score at randomization. Increase in Change of BARS global score indicates an increase in akathisia.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Change in Barnes Akathisia Rating Scale (BARS) Global Score
-0.07 units on scale
Standard Deviation 0.43
-0.09 units on scale
Standard Deviation 0.45

SECONDARY outcome

Timeframe: Randomization to Day 7

Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.

AIMS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4. Change : total score at day 7 minus total score at randomization. Increase in Change of total score indicates an increase in abnormal voluntary movements.

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Change in Abnormal Involuntary Movement Scale (AIMS) Total Score
-0.01 units on scale
Standard Deviation 0.3
-0.04 units on scale
Standard Deviation 0.4

SECONDARY outcome

Timeframe: From start of the study treatment to last dose plus 30 days

Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.

Number of patients with adverse events potentially associated with EPS collected by MedDRA Preferred Terms as akathisia, extrapyramidal disorder, restlessness

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Number of Patients With Potential Extrapyramidal Symptoms (EPS)
8 Patients
2 Patients

SECONDARY outcome

Timeframe: From start of the study treatment to last dose plus 30 days

Number of patients with adverse events potentially associated with somnolence collected by MedDRA Preferred Terms as lethargy, sedation, somnolence

Outcome measures

Outcome measures
Measure
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
Number of Patients With Potential Somnolence
11 Patients
12 Patients

Adverse Events

Quetiapine IR

Serious events: 0 serious events
Other events: 33 other events
Deaths: 0 deaths

Quetiapine XR

Serious events: 3 serious events
Other events: 29 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Quetiapine IR
n=69 participants at risk
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 participants at risk
Quetiapine fumarate Extended Release
Nervous system disorders
Convulsion
0.00%
0/69
1.4%
1/70
Psychiatric disorders
Depression
0.00%
0/69
1.4%
1/70
Psychiatric disorders
Suicide Attempt
0.00%
0/69
1.4%
1/70

Other adverse events

Other adverse events
Measure
Quetiapine IR
n=69 participants at risk
Quetiapine fumarate Immediate Release
Quetiapine XR
n=70 participants at risk
Quetiapine fumarate Extended Release
Gastrointestinal disorders
Dry Mouth
13.0%
9/69
21.4%
15/70
Metabolism and nutrition disorders
Increased Appetite
15.9%
11/69
15.7%
11/70
Nervous system disorders
Dizziness
15.9%
11/69
5.7%
4/70
Nervous system disorders
Headache
11.6%
8/69
5.7%
4/70
Nervous system disorders
Somnolence
7.2%
5/69
10.0%
7/70
General disorders
Fatigue
4.3%
3/69
8.6%
6/70
Nervous system disorders
Sedation
5.8%
4/69
7.1%
5/70
Cardiac disorders
Tachycardia
8.7%
6/69
4.3%
3/70
Nervous system disorders
Akathisia
5.8%
4/69
1.4%
1/70
Gastrointestinal disorders
Nausea
1.4%
1/69
5.7%
4/70

Additional Information

Gerard Lynch

AstraZeneca

Results disclosure agreements

  • Principal investigator is a sponsor employee The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca
  • Publication restrictions are in place

Restriction type: OTHER